Tagged with MSD

Coronavirus IFPMA Director General Thomas B. Cueni shares the outcomes of a recent high level pharma industry media briefing on the search for a COVID-19 treatment; highlighting the unprecedented levels of collaboration being demonstrated as key industry players work towards a common goal.*   Last week, high-level representatives from seven companies…

Belgium In 2020 PharmaBoardroom sat down with several key stakeholders in Belgian pharma to discuss company strategy, the Belgian healthcare landscape at large, and the country’s role within the wider European and global ecosystem. Here we highlight some of the key themes of the discussions: innovation, generics and biosimilars, and teamwork.…

Sweden Sweden’s USD 4.8 billion pharmaceutical market, its population size of 10 million and marginal positioning on the northerly fringe of the European Union all belie a legacy as a real titan of life sciences.* The country that has introduced some of the most impactful healthcare inventions of the 20th century…

Morocco Alain Barry, managing director of MSD in Morocco, shares how the organization is partnering with the Moroccan healthcare community to ensure that patients have access to innovative therapies and vaccines.   Morocco has been a pioneer in the region in the field of immunization by introducing innovative vaccines in the…

Belgium Despite a population size of only 11.4 million (ninth in Europe), Belgium is the continent’s fifth biggest spender on R&D, behind only Germany, Switzerland, the UK, and France according to the latest EFPIA data. The country has a long-established tradition of excellence in clinical trials and AmCham Belgium estimates that…

Belgium Luxembourg Brecht Vanneste, associate VP and managing director of MSD in Belgium and Luxembourg, highlights the strategic significance of the affiliate as an important location for early-stage clinical trials and home to the company’s Heist-op-den-Berg production facility, a key manufacturing site for the global group. Vanneste delivers a strong message about…

Global To celebrate International Women’s Day 2020, PharmaBoardroom brings you insights from some of the most inspirational female industry leaders we have had the privilege of talking to over the past 12 months.   Janet Woodcock, Director, Center for Drug Evaluation and Research (CDER), US FDA     Science really can…

Belgium Over the past few decades, pharma multinationals have been increasingly drawn to the highly cost-competitive markets of Central Eastern Europe (CEE) and Asia to situate major manufacturing sites. However, despite a comparatively expensive location, Belgium’s strong industrial heritage and manufacturing expertise is helping to maintain the country as a strategic…

Belgium There are over 3.5 million diagnoses and 1.3 million deaths from cancer in the EU each year and cancer is set to become the region’s leading cause of death without a reversal of current trends. Against this backdrop, the European Commission is launching the ‘Europe’s Beating Cancer Plan’ to reduce…

Europe Speaking at the 2020 European Cancer Forum in Brussels, MSD’s Deepak Khanna outlines the progress that the company is making at the forefront of oncological innovation, the importance of multi-stakeholder collaboration, and the potential impact of a Europe-wide cancer plan.   As health stakeholders, we need to work across the…

Sweden Key stakeholders in Swedish pharma explain why Sweden’s record on cancer care is the best in Europe and what more still needs to be done.   National investments in cancer care have improved patient outcomes and reduced waiting times Malin Parkler, Pfizer With an estimated 18 million cases globally in…

Puerto Rico Merck (MSD outside of the USA) is celebrating its 70-year anniversary in Puerto Rico this year. Executive Managing Director Wendy Perry highlights the company’s extensive footprint on the island which includes commercial, manufacturing and clinical research operations. She stresses the importance of maintaining a strong commercial presence locally to address…